Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SQuip is a U.S. consumer health company focused on drug-free nasal, ear-care, and respiratory-support products for adults, children, and infants. Its portfolio includes nasal irrigation systems, nasal and oral aspirators, earwax removal products, saline-based care products, and related wellness devices marketed under brands such as Nasaline, NasaKleen, Baby NasaKleen, Kyrosol, Andas, Salitair, and Snooze. The business originated from CAMEXCO, began commercializing Nasaline in North America in 2002, and was renamed SQUIP in 2007. SQuip and ENTpro were purchased by the owners of NeilMed Pharmaceuticals in 2018, and Squip, Inc. became part of NeilMed Pharmaceuticals on July 1, 2020. Today the brand operates as part of NeilMed's OTC nasal-care portfolio and sells established commercial products rather than a traditional drug-development pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SQuip.